ALK-Abello A/S (Alk) is a specialty pharmaceutical company involved in developing products for allergy treatment, prevention and diagnosis. The company principally focuses on allergy vaccination. Its product line consists of allergy diagnosis products including skin-prick tests (Soluprick SQ) and EpiPen, an auto-injector containing adrenaline used for emergency treatment of severe allergic reactions. The company has its operations spread across the world with its headquarters at Horsholm, Denmark.The company reported revenues of (Danish Krone) DKK 1,784.00 million during the fiscal year ended December 2008, an increase of 7.99% over 2007. The operating profit of the company was DKK 119.00 million during the fiscal year 2008, a decrease of 45.41% from 2007. The net profit of the company was DKK 95.00 million during the fiscal year 2008, a decrease of 46.33% from 2007.